2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N9914
    D-Psicose 551-68-8 ≥98.0%
    D-psicose is an orally active rare sugar. D-psicose inhibits p38-MAPK phosphorylation and MCP-1 expression. D-psicose inhibits the AGEs/RAGE/NF-κB pathway. D-psicose protects pancreatic β-islets, improves hyperglycemia and high-fat diet-induced non-alcoholic fatty liver disease.
    D-Psicose
  • HY-108527
    CD1530 107430-66-0 ≥98.0%
    CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases).
    CD1530
  • HY-126752
    Ophthalmic acid 495-27-2 99.91%
    Ophthalmic acid is a ubiquitous metabolite and glutathione modulator, with a Ki of 0.95 mM for glyoxalase I. Ophthalmic acid competitively inhibits glyoxalase I, glutathione S-transferase, glutaredoxin, glutamate-cysteine ligase, protein disulfide reductase (glutathione), as well as non-selective cation channels. Ophthalmic acid is applicable in diabetes-related research.
    Ophthalmic acid
  • HY-131368
    α,α-Trehalose 6-phosphate potassium 136632-28-5 ≥99.0%
    α,α-Trehalose 6-phosphate (Tre6P) potassium is a glucose analogue with potent anti-hyperglcaemic activity. α,α-Trehalose 6-phosphate potassium is rapidly converted to the end product, α,α′-trehalose, through the action of α,α-Trehalose 6-phosphate phosphatase (T6PP).
    α,α-Trehalose 6-phosphate potassium
  • HY-14771A
    Imeglimin hydrochloride 775351-61-6 99.98%
    Imeglimin hydrochloride (EMD 387008) is an oral glucose-lowering agent. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.
    Imeglimin hydrochloride
  • HY-145934A
    UDP-GlcNAz disodium 1611490-64-2 99.74%
    UDP-GlcNAz disodium is the analogue of UDP-GlcNAc disodium (HY-112174). UDP-GlcNAc disodium is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GlcNAc from the nucleotide sugar to a saccharide or peptide acceptor. UDP-GlcNAc disodium is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    UDP-GlcNAz disodium
  • HY-N0420S1
    Succinic acid-d4 14493-42-6 99.91%
    Succinic-2,2,3,3-d4 acid is the deuterium labeled Succinic acid. Succinic acid is an intermediate product of the tricarboxylic acid cycle, as well as one of fermentation products of anaerobic metabolism.
    Succinic acid-d4
  • HY-N0729S2
    Linoleic acid-13C18 287111-25-5
    Linoleic acid-13C18 is the 13C labeled Linoleic acid. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism .
    Linoleic acid-13C18
  • HY-W019670
    N4-Acetylcytidine 3768-18-1
    N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity.
    N4-Acetylcytidine
  • HY-125944
    MitoTEMPO hydrate 1569257-94-8 98.03%
    MitoTEMPO hydrate is a mitochondria-targeted antioxidant. MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke.
    MitoTEMPO hydrate
  • HY-Y0262B
    Sodium oxalate,ACS,99.5% 62-76-0 99.65%
    Sodium oxalate is an orally active dispersant and coordination agent. Sodium oxalate causes mitochondrial dysfunction. Sodium oxalate has catalytic enhancing activity. Sodium oxalate induces stable chronic kidney disease. Sodium oxalate induces highly malignant and undifferentiated breast tumors.
    Sodium oxalate,ACS,99.5%
  • HY-W018035
    DL-Glyceric Acid (20% in water) 473-81-4
    DL-Glyceric Acid (20% in water) is a metabolite of plants and mammals and exists in two configurations, D and L.
    DL-Glyceric Acid (20% in water)
  • HY-W399297
    Isodeoxycholic acid 566-17-6 ≥98.0%
    Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is a 3β-hydroxylated secondary bile acid. Isodeoxycholic acid is produced by epimerization of deoxycholic acid by intestinal bacteria. Isodeoxycholic acid is detectable in feces, mainly existing as saponifiable conjugates with long-chain fatty acids. Isodeoxycholic acid participates in the regulation of intestinal physiology.
    Isodeoxycholic acid
  • HY-50898A
    Lapatinib ditosylate 388082-77-7 99.98%
    Lapatinib ditosylate (GW572016 ditosylate) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
    Lapatinib ditosylate
  • HY-11068
    SB 239063 193551-21-2
    SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD. SB 239063 can penetrate the blood brain barrier (BBB).
    SB 239063
  • HY-112233
    O-304 1261289-04-6 99.59%
    O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a agent to treat type 2 diabetes (T2D) and associated cardiovascular complications .
    O-304
  • HY-127105A
    Iptacopan hydrochloride 1646321-63-2 99.88%
    Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).
    Iptacopan hydrochloride
  • HY-N0010
    Geniposidic acid 27741-01-1 98.87%
    Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis.
    Geniposidic acid
  • HY-B0782A
    Acetazolamide sodium 1424-27-7 99.54%
    Acetazolamide sodium is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities.
    Acetazolamide sodium
  • HY-100806S
    Kynurenic acid-d5 350820-13-2 99.85%
    Kynurenic acid-d5 is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
    Kynurenic acid-d5
Cat. No. Product Name / Synonyms Application Reactivity